Show simple item record

dc.contributor.authorDowsett, M
dc.contributor.authorSestak, I
dc.contributor.authorBuus, R
dc.contributor.authorLopez-Knowles, E
dc.contributor.authorMallon, E
dc.contributor.authorHowell, Anthony
dc.contributor.authorForbes, J
dc.contributor.authorBuzdar, A
dc.contributor.authorCuzick, J
dc.date.accessioned2015-07-21T10:31:18Zen
dc.date.available2015-07-21T10:31:18Zen
dc.date.issued2015-06-15en
dc.identifier.citationEstrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. 2015, 21 (12):2763-70 Clin Cancer Resen
dc.identifier.issn1078-0432en
dc.identifier.pmid26078431en
dc.identifier.doi10.1158/1078-0432.CCR-14-2842en
dc.identifier.urihttp://hdl.handle.net/10541/560787en
dc.description.abstractTo identify the individual genes or gene modules that lead to the OncoptypeDx 21-gene recurrence score's reduced performance after 5 years and thereby identify indices of residual risk that may guide selection of patients for extended adjuvant therapy.
dc.language.isoenen
dc.rightsArchived with thanks to Clinical cancer research : an official journal of the American Association for Cancer Researchen
dc.titleEstrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Canceren
dc.typeArticleen
dc.contributor.departmentRoyal Marsden Hospital and Breakthrough Breast Cancer Centre, Institute of Cancer Research, London, United Kingdomen
dc.identifier.journalClinical Cancer Researchen
refterms.dateFOA2020-05-01T14:11:52Z
html.description.abstractTo identify the individual genes or gene modules that lead to the OncoptypeDx 21-gene recurrence score's reduced performance after 5 years and thereby identify indices of residual risk that may guide selection of patients for extended adjuvant therapy.


Files in this item

Thumbnail
Name:
2763.full.pdf
Size:
428.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record